Research programme: bacteriophage therapies - Pherecydes

Drug Profile

Research programme: bacteriophage therapies - Pherecydes

Alternative Names: P. aeruginosa phage therapy - Pherecydes; PP 1231; PP 2351; S. aureus phage therapy - Pherecydes

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pherecydes Pharma
  • Class Bacteriophages; Pseudomonas phages; Staphylococcus phages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bone and joint infections; Respiratory tract infections

Most Recent Events

  • 29 Aug 2016 Pherecydes Pharma plans phase I/II trials for Bone and joint infections and Respiratory tract infections (Pherecydes pipeline, August 2016)
  • 29 Aug 2016 Preclinical trials in Bone and joint infections in France (unspecified route) (Pherecydes Pharma pipeline, August 2016)
  • 29 Aug 2016 Preclinical trials in Respiratory tract infections in France (Inhalation) (Pherecydes Pharma pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top